Please login to the form below

Not currently logged in
Email:
Password:

MNK-795

This page shows the latest MNK-795 news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offers $1.3bn for Cadence Pharma

company.". Mallinckrodt is also active in the analgesia sector and last year won priority review status from the FDA for MNK-795, a controlled-release oral formulation of oxycodone and acetaminophen

Latest news

  • FDA grants priority review to pain drug

    FDA grants priority review to pain drug. Mallinckrodt’ s MNK-795 is intended for the management of moderate to severe acute pain. ... Mallinckrodt has won priority review from the US Food and Drug Administration (FDA) for its pain drug MNK-795.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics